{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cervical+Cancer&page=2",
    "query": {
      "condition": "Neuroendocrine Cervical Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cervical+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:50:00.973Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00923247",
      "title": "A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Medullary Thyroid Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Vandetanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 22,
      "start_date": "2009-02-19",
      "completion_date": "2016-12-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923247"
    },
    {
      "nct_id": "NCT00358956",
      "title": "A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "ZD6474 (vandetanib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2006-08",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • Boston, Massachusetts",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00358956"
    },
    {
      "nct_id": "NCT03849469",
      "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Triple Negative Breast Cancer",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Carcinoma",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced or Metastatic Solid Tumors",
        "Prostate Carcinoma",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Squamous Cell Anal Cancer",
        "Squamous Cell Penile Carcinoma",
        "Squamous Cell Vulvar Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "XmAb®22841",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (Keytruda®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-05-29",
      "completion_date": "2023-02-16",
      "has_results": false,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 28,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03849469"
    },
    {
      "nct_id": "NCT02986867",
      "title": "SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Melanoma",
        "Cervical Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "SAbR Treatment of Lesions",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2017-06-13",
      "completion_date": "2018-03-07",
      "has_results": false,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02986867"
    },
    {
      "nct_id": "NCT00132704",
      "title": "An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Neoplasms",
        "Colorectal Neoplasms",
        "Melanoma",
        "Small Cell Lung Cancer",
        "Liposarcoma"
      ],
      "interventions": [
        {
          "name": "Ionizing radiation (IR) therapy",
          "type": "RADIATION"
        },
        {
          "name": "Ionizing radiation (IR)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 149,
      "start_date": "2004-08",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00132704"
    },
    {
      "nct_id": "NCT02748564",
      "title": "Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Stage III Mucosal Melanoma of the Head and Neck",
        "Stage IIIA Skin Melanoma",
        "Stage IIIB Skin Melanoma",
        "Stage IIIC Skin Melanoma",
        "Stage IV Skin Melanoma",
        "Stage IVA Mucosal Melanoma of the Head and Neck",
        "Stage IVB Mucosal Melanoma of the Head and Neck",
        "Stage IVC Mucosal Melanoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-03-21",
      "completion_date": "2023-06-05",
      "has_results": true,
      "last_update_posted_date": "2023-08-03",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 5,
      "location_summary": "Maywood, Illinois • Bloomington, Indiana • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748564"
    },
    {
      "nct_id": "NCT02637531",
      "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors (Part A/B/C/D)",
        "Non-small Cell Lung Cancer (Part E)",
        "Melanoma (Part E)",
        "Squamous Cell Cancer of the Head and Neck (Part E)",
        "Triple Negative Breast Cancer (Part F)",
        "Adrenocortical Carcinoma (Part G)",
        "Mesothelioma (Part G)",
        "High-circulating Myeloid-derived Suppressor Cells (Part H)"
      ],
      "interventions": [
        {
          "name": "IPI-549 (eganelisib)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2015-12",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637531"
    },
    {
      "nct_id": "NCT04254107",
      "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Gastric Carcinoma",
        "Gastroesophageal Junction Carcinoma",
        "Classical Hodgkin Lymphoma",
        "Diffuse Large B-cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Cutaneous Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "SEA-TGT",
          "type": "DRUG"
        },
        {
          "name": "sasanlimab",
          "type": "DRUG"
        },
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2020-05-29",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04254107"
    },
    {
      "nct_id": "NCT02576431",
      "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors Harboring NTRK Fusion"
      ],
      "interventions": [
        {
          "name": "BAY2757556 (Larotrectinib, Vitrakvi)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2015-09-30",
      "completion_date": "2025-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 18,
      "location_summary": "Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02576431"
    },
    {
      "nct_id": "NCT06910657",
      "title": "IDOV-Immune for Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Melanoma",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Hepatocellular Carcinoma",
        "Renal Cell Carcinoma",
        "Breast Cancer",
        "Sarcoma",
        "Bladder Cancer",
        "Lung Cancer",
        "Prostate Cancer",
        "Cervical Cancers",
        "Head and Neck Cancers",
        "Adrenal Gland Tumors"
      ],
      "interventions": [
        {
          "name": "IDOV-Immune (oncolytic vaccinia virus)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ViroMissile, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2025-08-25",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-05-22T07:50:00.973Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06910657"
    }
  ]
}